Background: Percutaneous lymphatic intervention (PCL) is a promising new therapy
| INTRODUCTION
Plastic bronchitis (PB) is an uncommon, but potentially life-threatening complication that can occur in patients after surgical repair of congenital heart disease. The estimated prevalence of PB after Fontan palliation is 4% and 5-year mortality is estimated up to 50%. 1, 2 While PB has also been reported in patients with sickle cell disease, chronic lung diseases, and primary lymphatic abnormalities, it is most widely described in patients with surgically repaired congenital heart disease (CHD). [3] [4] [5] PB is characterized by production of bronchial casts in the airway. Casts are composed of cellular and proteinaceous material that solidifies in the tracheobronchial tree. While smaller casts can be expectorated spontaneously, larger casts often pose significant risk for airway obstruction and require bronchoscopic removal.
Although the etiology of PB is not fully understood, recent advances in lymphatic imaging techniques have provided insight into underlying abnormalities in lymphatic flow associated with PB, including pulmonary lymphatic perfusion syndrome (PLPS). 6 These lymphatic abnormalities, combined with elevated central venous pressure and low cardiac output, are thought to cause inflammation and injury to the alveoli and surrounding capillaries. 2, [7] [8] [9] Loss of alveolar-capillary membrane integrity facilitates exudation of material into the airways leading to cast formation.
The initial cast morphology classification system for cast morphology distinguished cellular inflammatory casts from acellular casts made of mucin and fibrin. 4 Originally, patients with CHD were thought to have mucin-predominant acellular casts secondary to mucin hypersecretion in the airways. More recent cast analysis in CHD patients revealed both a high fibrin predominance and lymphocyte-predominant cellularity. 3, 10 The current proposed classification system distinguishes casts on the basis of their underlying etiology, namely structural CHD, primary lymphatic disorders, and non-lymphatic disorders. 3 Percutaneous lymphatic intervention (PCL) with thoracic duct embolization is the preferred approach for treating patients with PB at our institution. 6, 18 Flexible bronchoscopy is performed immediately prior to intervention to assess for cast burden and airway injury.
In this study, we aimed to characterize bronchoalveolar lavage 
| Lymphatic imaging and intervention
The central lymphatic system was initially imaged with dynamic contrast-enhanced magnetic resonance lymphangiogram (DCMRL) and T2-weighted MRI as previously described by Dori et al. [18] [19] [20] Hemodynamic cardiac catheterization was performed prior to the lymphatic intervention in each case. Intranodal lymphangiography was used to visualize the lymphatic vessels, as described by Nadolski and Itkin. 21 Thoracic duct access was then obtained through a percutaneous transabdominal approach. Complete embolization of the thoracic duct or selective embolization of lymphatic branches was performed using the techniques reported by Dori et al. 
| Cast analysis
Casts were included for analysis if they were collected within 1 month 
| Intermediate term follow-up
Families were contacted via telephone to inquire about postintervention outcomes. All phones calls were conducted between January 2018 and April 2018 using a standardized questionnaire to uniformly collect data on casting frequency, cast appearance, respiratory support and medications, and post-intervention surgical procedures.
| Statistical methods
Standard descriptive statistics were used to summarize demographic, historical, bronchoscopic, intervention, and morphology variables. Two-tailed P-values were considered statistically significant if <0.05.
| RESULTS
We identified 62 patients with plastic bronchitis and surgically repaired CHD who underwent PCL at our institution from August 2013 to October 2017. Baseline characteristics for the cohort are summarized in Table 1 . The majority (87%) of patients had Fontan physiology at time of intervention, defined as single ventricle physiology with total (superior and inferior) cavopulmonary connection. Two patients had only completed superior cavopulmonary connection, resulting in Glenn physiology. The six patients with 2-ventricle physiology included one patient with congenital heart disease status-post orthotopic heart transplantation prior to the intervention. Three patients in the cohort initially had lymphatic procedures attempted that were halted due to inability to access the thoracic duct. All three patients had subsequent lymphatic interventions successfully completed on their second attempt, which we considered the index procedure for inclusion.
The median times from most recent cardiac surgery before PB diagnosis to the onset of PB and from PB onset to PCL were 20 months (IQR 4-47 months) and 9 months (IQR 4-34 months), respectively. The majority (90%) of patients had evidence of casting within 1 month prior to the intervention. Pre-intervention casting frequency was variable, with 31% of patients casting daily, 26% casting weekly, 21% casting every few weeks, and 11% casting monthly (Table 1) . 
| Bronchoscopy results

| Cast analysis results
The gross morphology of a cast removed during bronchoscopy is shown in Figure 2A . Nineteen patients produced one or more casts within 1 month of procedure, which were analyzed separately as 23 cast specimens (Table 3) . Twenty-one casts were removed during the bronchoscopy concurrent with intervention, one was spontaneously expectorated, and one was removed from a patient's gastrostomy tube.
All 23 cast specimens contained scattered lymphocytes. Nineteen (83%) casts were composed of dense proteinaceous material ( Figure 2B ). Looser basophilic mucin that contained muciphages was Pre-intervention and post-intervention respiratory medications and support for the remaining 44 patients transplanted were
analyzed. There was a statistically significant reduction in the need for inhaled tPA and respiratory support (Table 4) . A number of patients were also being treated with albuterol, inhaled steroids, hypertonic saline, dornase alfa, montelukast, azithromycin, and systemic steroids. While none of these specific medications, except for inhaled tPA, have been shown to be reliably effective in the treatment of PB, there were statistically significant reductions in all medications except montelukast and systemic steroids post-intervention. In addition to these changes in respiratory therapies, there was a significant decrease in casting frequency at intermediate-term
follow-up (P < 0.0001). In those patients with continued casting after initial intervention, 79% reported that casts expectorated postintervention appeared smaller than those expectorated preintervention.
| DISCUSSION
In this study, we characterize BALs and cast morphology in patients with surgically repaired CHD and PB at time of lymphatic intervention.
We sought to assess bronchoscopy safety and intervention efficacy by quantifying respiratory outcomes post-intervention. This study provides the largest cohort of patients with PB to date and provides a homogenous cohort due to common underlying congenital heart disease.
In our cohort we were able to demonstrate successful removal of casts with flexible bronchoscopy in a controlled setting without respiratory complications or airway obstruction. While not used in this current cohort, further advancement in our technique of cast removal has included the use of CryoProbe, which has enhanced our ability to remove casts.
Our study is the first to describe the BAL characteristics of patients with PB. We hypothesized that casts containing neutrophils and/or eosinophils would be associated with neutrophilic BALs. Our study demonstrates higher counts of neutrophils and decreased counts of macrophages in patients with PB at the time of BAL collection in comparison to healthy children and adults. 22, 23 Of note, while 42% of patients had elevated lymphocytes on BAL, the median BAL lymphocyte count was comparable to that of healthy children and adults. These findings are unexpected given that bronchial casts are thought to derive from the lymphatic system, and we would expect BAL lymphocyte count to be elevated. 
| Limitations
Our study has several important limitations. First, this is a retrospective single-center study and therefore may not represent the whole population of patients with surgically repaired CHD and PB. Our institution is currently the only one performing PCL, and therefore, there may be a selection bias in the patients represented in this cohort. Cast composition may have been altered in patients who had been treated with fibrinolytic and anti-infective medications. Some patients were unable to be contacted by phone for follow up, which may reflect response bias. If non-responders had worse outcomes, then our findings would overestimate intervention efficacy. While our study demonstrates reduced need in CHD patients for respiratory therapies post-intervention, it may not be appropriate to extrapolate these outcomes to patients with PB secondary to a non-cardiac etiology. 
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